ORPHA:401964
Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Also known as: Autosomal dominant hereditary motor and sensory neuropathy type 2 with giant axons · CMT2 with giant axons · HMSN2 with giant axons
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
4
12.1th percentile
Trials
0
Interventional, condition-specific
Researchers
31
Distinct authors in sample
Gene link
DCAF8
Moderate
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare subtype of axonal motor and sensory characterized by distal muscle weakness and atrophy (principally of peroneal muscles) associated with distal sensory loss (tactile, vibration), pes cavus present since infancy or childhood, and axonal swelling with neurofilament accumulation on nerve biopsy. Other features may include hand muscle involvement, hypo/arreflexia, gait disturbances, muscle cramps, toe abnormalities and mild .
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0012411
- OMIM:610100
- UMLS:C1864695
Additional Mondo synonyms (4)
DCAF8 giant axonal neuropathy · autosomal dominant hereditary motor and sensory neuropathy type 2 with giant axons · giant axonal neuropathy caused by mutation in DCAF8 · giant axonal neuropathy type 2
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Moderate — DCAF8
- LiteraturePresent
4 matched papers (2 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Probably — there is moderate evidence for DCAF8.
GenCC classification: Moderate.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
4
4 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
4 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2 in the last 10 years · high confidence · 12.1th percentile (publications denominator)
Phrase hits: 4 · MeSH hits: 0
Who's working on it?
31
Distinct author names in 4 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Agrawal PB1 paper · 2023
Division of Genetics and Genomics Boston Children's Hospital Harvard Medical School Boston MA 02115 USA.
Papers in Europe PMC - 02Atkinson EJ1 paper · 2014Papers in Europe PMC
- 03Bauer S1 paper · 2023
Department of Urology Boston Children's Hospital Boston MA 02115 USA.
Papers in Europe PMC - 04Beggs AH1 paper · 2023
Division of Genetics and Genomics Boston Children's Hospital Harvard Medical School Boston MA 02115 USA.
Papers in Europe PMC - 05Berde C1 paper · 2023
The Manton Center for Orphan disease Research Boston Children's Hospital Harvard Medical School Boston MA 02115 USA.
Papers in Europe PMC - 06Bönnemann C1 paper · 2014Papers in Europe PMC
- 07Botuyan MV1 paper · 2014Papers in Europe PMC
- 08Brownstein CA1 paper · 2023
Division of Genetics and Genomics Boston Children's Hospital Harvard Medical School Boston MA 02115 USA.
Papers in Europe PMC - 09Duan X1 paper · 2014Papers in Europe PMC
- 10Dyck PJ1 paper · 2014Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category Charcot-Marie-Tooth disease type 2 also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: Charcot-Marie-Tooth disease type 2
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons" OR "Autosomal dominant hereditary motor and sensory neuropathy type 2 with giant axons" OR "CMT2 with giant axons" OR "HMSN2 with giant axons" OR "DCAF8 giant axonal neuropathy" OR "giant axonal neuropathy caused by mutation in DCAF8" OR "giant axonal neuropathy type 2"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons" OR "Autosomal dominant hereditary motor and sensory neuropathy type 2 with giant axons" OR "CMT2 with giant axons" OR "HMSN2 with giant axons" OR "DCAF8 giant axonal neuropathy" OR "giant axonal neuropathy caused by mutation in DCAF8" OR "giant axonal neuropathy type 2" OR "DCAF8"
Recall-expansion terms: DCAF8
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Charcot-Marie-Tooth disease type 2"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:28:52.244Z